Sotrovimab

索托韦单抗

Report date: 2026/03/16 20:01:47

Base Information

Drug NameSotrovimab
Drug Alias NameXevudyVIR-7831GSK-4182136
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHematologic Neoplasms +[4] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryAustralia
Original Approved Date2021/08/23
Country/TerritoryCanadaUnited StatesUkraine +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVir Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesEuropean CommissionGlaxosmithkline PlcGlaxosmithkline Uk Ltd +[5] 
Inactive CompaniesGlaxosmithkline Trading Services Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsSolid tumoursHematologic NeoplasmsLymphoma

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG